Shopping Cart
Remove All
Your shopping cart is currently empty
Xanthine oxidase-IN-23
Copy Product Info
🥰Excellent
Synonyms:
Catalog No. T219031 Copy Product Info
🥰Excellent
Xanthine oxidase-IN-23 (Compound BPF) is an orally active, reversible, mixed-type inhibitor of xanthine oxidase with an IC50 of 3.33 μM. It directly binds to XOD in a reversible mixed-type manner, inhibiting its catalytic activity. Additionally, Xanthine oxidase-IN-23 increases ABCG2 and decreases GLUT9 expression to facilitate renal uric acid excretion. This compound reduces serum uric acid levels and improves kidney function in hyperuricemic mice, making it useful for hyperuricemia research.
Xanthine oxidase-IN-23
Cas No. 3055112-52-9
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Xanthine oxidase-IN-23 (Compound BPF) is an orally active, reversible, mixed-type inhibitor of xanthine oxidase with an IC50 of 3.33 μM. It directly binds to XOD in a reversible mixed-type manner, inhibiting its catalytic activity. Additionally, Xanthine oxidase-IN-23 increases ABCG2 and decreases GLUT9 expression to facilitate renal uric acid excretion. This compound reduces serum uric acid levels and improves kidney function in hyperuricemic mice, making it useful for hyperuricemia research. |
| In vitro | Xanthine oxidase-IN-23 (15 min) effectively inhibits purified xanthine oxidase through a reversible mixed-type inhibition with an IC₅₀ of 3.33 μM. Additionally, Xanthine oxidase-IN-23 (0.5-8 μM) exhibits strong DPPH radical scavenging activity, achieving over 50% scavenging at a concentration of 2 μM. |
| In vivo | Xanthine oxidase-IN-23 (BPF) (100-200 mg/kg; oral administration) effectively reduces serum uric acid levels in hyperuricemic mice in a dose-dependent manner by inhibiting liver XOD activity and regulating kidney urate transporters. Additionally, it prevents hyperuricemia-induced kidney damage without causing liver injury. |
| Molecular Weight | 456.08 |
| Formula | C17H12Br2O5 |
| Cas No. | 3055112-52-9 |
| Smiles | O=C(C=CC=1C=C(O)C(O)=CC1Br)C=CC=2C=C(O)C(O)=CC2Br |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: Xanthine oxidase-IN-23 in vivo | Xanthine oxidase-IN-23 in vitro | Xanthine oxidase-IN-23 formula | Xanthine oxidase-IN-23 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.